J Ghosn

Summary

Country: France

Publications

  1. ncbi Acute hepatitis C in HIV-infected men who have sex with men
    J Ghosn
    Departement des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    HIV Med 5:303-6. 2004
  2. ncbi Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial
    J Ghosn
    Service des Maladies Infectieuses, Hopital Pitie Salpetriere, Paris, France
    HIV Med 8:142-7. 2007
  3. ncbi HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time
    Jade Ghosn
    Laboratoire de Virologie, CHU Necker Enfants Malades, Université René Descartes Paris, France
    AIDS 20:159-70. 2006
  4. ncbi [Sexual transmission of hepatitis C virus]
    Jade Ghosn
    Laboratoire de Virologie, Universite Rene Descartes Paris V, EA MRT 3620, CHU Necker Enfants Malades, Paris
    Presse Med 34:1034-8. 2005
  5. ncbi Muscle and liver lactate metabolism in HAART-treated and naive HIV-infected patients: the MITOVIR study
    Jade Ghosn
    Department des Maladies Infectieuses, CHU Pitie Salpetriere, AP HP, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 10:543-50. 2005
  6. ncbi Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men
    Jade Ghosn
    Laboratoire de Virologie, EA MRT 3620 Université R Descartes, CHU Necker, Paris
    AIDS 18:447-57. 2004
  7. ncbi [Tolosa-Hunt syndrome revealing Burkitt lymphoma in an HIV-seropositive patient]
    Jade Ghosn
    Département de Maladies Infectieuses et Tropicales, CHU Pitie Salpetriere, Paris 75
    Presse Med 32:1319-22. 2003
  8. ncbi Atypical toxoplasmic manifestation after discontinuation of maintenance therapy in a human immunodeficiency virus type 1-infected patient with immune recovery
    Jade Ghosn
    Departement des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire Pitié Paris, France
    Clin Infect Dis 37:e112-4. 2003
  9. ncbi Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France
    Marie Laure Chaix
    Université Paris Descartes EA 3620, AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    AIDS 23:717-24. 2009
  10. ncbi X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI
    Jade Ghosn
    Universite Paris Descartes, EA 3620, CHU Necker Enfants Malades, Paris, France
    PLoS ONE 6:e23301. 2011

Detail Information

Publications42

  1. ncbi Acute hepatitis C in HIV-infected men who have sex with men
    J Ghosn
    Departement des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    HIV Med 5:303-6. 2004
    ....
  2. ncbi Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial
    J Ghosn
    Service des Maladies Infectieuses, Hopital Pitie Salpetriere, Paris, France
    HIV Med 8:142-7. 2007
    ..88 log(10) HIV-1 RNA copies/mL. The magnitude of the reduction in viral load suggested that lower doses might still be effective while offering adequate safety during long-term use...
  3. ncbi HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time
    Jade Ghosn
    Laboratoire de Virologie, CHU Necker Enfants Malades, Université René Descartes Paris, France
    AIDS 20:159-70. 2006
    ....
  4. ncbi [Sexual transmission of hepatitis C virus]
    Jade Ghosn
    Laboratoire de Virologie, Universite Rene Descartes Paris V, EA MRT 3620, CHU Necker Enfants Malades, Paris
    Presse Med 34:1034-8. 2005
    ..Sexual transmission of HCV may be enhanced by other concomitant sexually transmitted infections with genital erosive lesions or via traumatic sexual intercourse with abrasion of the genital mucosa...
  5. ncbi Muscle and liver lactate metabolism in HAART-treated and naive HIV-infected patients: the MITOVIR study
    Jade Ghosn
    Department des Maladies Infectieuses, CHU Pitie Salpetriere, AP HP, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 10:543-50. 2005
    ..To assess the impact of nucleoside analogue reverse transcriptase inhibitor (NRTI) combination therapy on muscle and liver lactate metabolism in HIV-infected patients...
  6. ncbi Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men
    Jade Ghosn
    Laboratoire de Virologie, EA MRT 3620 Université R Descartes, CHU Necker, Paris
    AIDS 18:447-57. 2004
    ..To study the genetic diversity of drug-resistant HIV strains present in blood and in semen, especially those archived in peripheral blood mononuclear cells (PBMC) and non-sperm cells (NSC)...
  7. ncbi [Tolosa-Hunt syndrome revealing Burkitt lymphoma in an HIV-seropositive patient]
    Jade Ghosn
    Département de Maladies Infectieuses et Tropicales, CHU Pitie Salpetriere, Paris 75
    Presse Med 32:1319-22. 2003
    ..It regresses rapidly with systemic corticosteroid therapy. Lymphomas involving the cavernous sinus may mimic a Tolosa-Hunt syndrome and hence delay diagnosis...
  8. ncbi Atypical toxoplasmic manifestation after discontinuation of maintenance therapy in a human immunodeficiency virus type 1-infected patient with immune recovery
    Jade Ghosn
    Departement des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire Pitié Paris, France
    Clin Infect Dis 37:e112-4. 2003
    ..This atypical recurrence was more likely to be a reinfection than a reactivation, as attested by the genotypic analysis of the Toxoplasma gondii strain recovered from the patient...
  9. ncbi Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France
    Marie Laure Chaix
    Université Paris Descartes EA 3620, AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    AIDS 23:717-24. 2009
    ....
  10. ncbi X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI
    Jade Ghosn
    Universite Paris Descartes, EA 3620, CHU Necker Enfants Malades, Paris, France
    PLoS ONE 6:e23301. 2011
    ..X4-tropic variants present at baseline were still exclusive (patients D and E) or dominant (at least one time point, patient C) far from PHI...
  11. ncbi Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection
    J Ghosn
    Laboratoire de Virologie, EA MRT 3620, Université René Descartes Paris5, CHU Necker Enfants Malades, 149 rue de Sevres, 75015 Paris, France
    Sex Transm Infect 82:458-60. 2006
    ..An increase in the incidence of sexually transmitted infections and hepatitis C virus (HCV) infections in HIV-infected men who have sex with men (MSM) has recently been reported...
  12. ncbi Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients
    Claudine Duvivier
    AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Maladies Infectieuses et Tropicales, Paris, France
    AIDS 23:817-24. 2009
    ..To evaluate the change in bone mineral density (BMD) at specific sites in patients initiating antiretroviral therapy in a substudy of the ANRS 121 trial...
  13. ncbi [Enhancing immune restoration in human immunodeficiency virus infection]
    S Sahali
    AP HP, Service de Medecine Interne et Maladies Infectieuses, CHU de Bicetre, 78, rue du General Leclerc, 94270 Le Kremlin Bicetre, France
    Rev Med Interne 32:425-31. 2011
    ..Here we review several current strategies that may improve immune reconstitution, keeping in mind that the best way to reach normal CD4T cell count is an early treatment initiation...
  14. ncbi [Legionellosis in HIV-1 infected patients. 4 case reports]
    D Sene
    Services de Maladies Infectieuses et Tropicales, Hopital Pitie Salpetriere, 47 83 Bd de l Hopital, Paris
    Presse Med 31:356-8. 2002
    ..Contrary to patients exhibiting cellular immunodepression, legionellosis is rare in HIV-infected patients. We report 4 cases...
  15. ncbi [Autoimmune myelofibrosis with dermatomyositis]
    S Sahali
    Service de Medecine Interne, CHU de Bicetre, AP HP, 78, rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Rev Med Interne 30:71-3. 2009
    ..We report a second observation of autoimmune myelofibrosis associated with an inflammatory myositis in a 30-year-old female. The links between myelofibrosis and autoimmunity are discussed...
  16. ncbi [Male genital tract infection: the point of view of the virologist]
    M Leruez-Ville
    Laboratoire de Virologie, université Paris Descartes EA MRT 3620, Faculté de Médecine AP HP, Hopital Necker Enfants Malades, 149, rue de Sevres, 75015 Paris, France
    Gynecol Obstet Fertil 33:684-90. 2005
    ..Recent advances in this field have allowed to offer Assisted reproductive techniques to couples with chronic viral infection, under strict and specific protocols. This paper presents an overview of these recent developments...
  17. ncbi Post-exposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multi-resistant HIV-infected source person
    Frédéric Méchaï
    1 AP HP, Internal Medicine and Infectious Diseases Department, Bicetre University Hospital, Paris XI University, Le Kremin Bicêtre, France
    J Med Virol 80:9-10. 2008
    ..Post-exposure prophylaxis was well tolerated, with no increase in liver function tests. The health care worker remained HIV-negative after a 6-month follow-up...
  18. ncbi HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART
    Cathia Soulie
    Department of Virology EA2387, Pitie Salpetriere Hospital, University Pierre et Marie Curie, Paris, France
    AIDS 21:2243-5. 2007
    ..This suggests that CCR5 antagonist activity should not be compromised in patients harbouring R5 viruses before starting HAART...
  19. ncbi Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients
    Jean Francois Delfraissy
    AP HP, Department of Internal Medicine and Infectious Diseases, Bicetre University Hospital, Le Kremlin Bicetre, France
    AIDS 22:385-93. 2008
    ..Guidelines for the use of antiretroviral agents for HIV-1 infection recommend combining at least three agents. The toxicity, cost, and complexity of such regimens warrant the search for other options...
  20. ncbi Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy
    Jade Ghosn
    AP HP, Department of Infectious Diseases, Pitie Salpetriere Hospital, 47 Boulevard de l Hopital, 75013 Paris, France
    Antimicrob Agents Chemother 52:1542-4. 2008
    ..At delivery, 26 of 28 women on indinavir-ritonavir had HIV RNA levels of <200 copies/ml. No infant was HIV infected. These data are encouraging for the use of this combination for prevention of mother-to-child transmission of HIV...
  21. ncbi Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus co-infected men who have sex with men
    Jade Ghosn
    AP HP, EA MRT 3620, Universite Paris Descartes, Department of Virology, Necker Hospital, Paris, France
    AIDS 22:658-61. 2008
    ..HCV serology and serum HCV RNA should be examined periodically in HIV-infected men who have sex with men engaging in high-risk sexual behaviours...
  22. ncbi Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine
    Jade Ghosn
    Laboratoire de Virologie, EA MRT 3620, Universite Rene Descartes Paris 5, CHU Necker Enfants Malades, Paris, France
    J Antimicrob Chemother 61:1344-7. 2008
    ..More than 80% of untreated HIV-infected men have detectable HIV-RNA in semen and such a strategy could favour local selection of resistant variants, given the poor penetration of most PIs in semen...
  23. ncbi Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection
    Sabrinel Sahali
    AP HP, Bicetre University Hospital, Department of Internal Medicine and Infectious Diseases, Paris Sud University, Le Kremlin Bicetre, France
    AIDS Rev 10:4-14. 2008
    ..The more frequent occurrence of low-level viremia, however, does not allow the widespread use of such a strategy outside of clinical studies at this time...
  24. ncbi Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial
    Claudine Duvivier
    AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Maladies Infectieuses et Tropicales, Paris F 75013, France
    J Antimicrob Chemother 62:797-808. 2008
    ..The aim of this study was to evaluate the impact on body fat of nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens compared with NRTI-containing therapy in HIV-1-infected antiretroviral (ARV)-naive patients...
  25. ncbi Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen
    Constance Delaugerre
    Virology Department, Saint Louis Hospital APHP, Paris, France
    AIDS 22:1809-13. 2008
    ..Limited data are available on resistance pattern emerging in patients failing DRV/r and on subsequent remaining protease inhibitor options...
  26. ncbi Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study
    Stephanie Dominguez
    Département des Maladies Infectieuses et Tropicales INSERM U720, CHU Pitie Salpetriere, Paris, France
    J Med Virol 79:105-10. 2007
    ..This add-on pilot study supports the concept of double dose tenofovir to virologically overcome the decreased sensitivity of NRTI-resistant viruses. However, the safety of this regimen needs to be considered carefully...
  27. ncbi Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy
    Hassane Izzedine
    Department of Nephrology, La Pitie Salpetriere Hospital, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie Paris IV, 75013 Paris, France
    J Infect Dis 194:1481-91. 2006
    ..Tenofovir disoproxil fumarate (TDF) may induce renal proximal tubulopathy (rPT). There are no data on pharmacogenomic predictors of rPT in the genes encoding the multidrug-resistance protein (MRP) 2 and MRP4 transporters...
  28. ncbi Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients
    Jade Ghosn
    Department of Infectious Diseases, Inserm EO214, , Paris, France
    AIDS 17:209-14. 2003
    ..Tolerability of RTV/IDV was excellent. CONCLUSION: RTV/IDV (100/400 mg bid) yields significantly higher IDV plasma Cmin and lower IDV Cmax values relative to the standard IDV regimen, thereby improving both tolerability and efficacy...
  29. ncbi Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy
    Marc Wirden
    Department of Virology, INSERM EMI 0214, Pitie Salpetriere Hospital, Paris, France
    Antimicrob Agents Chemother 48:644-7. 2004
    ....
  30. ncbi Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals
    Claudine Duvivier
    Department of Infectious Diseases, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 8:603-9. 2003
    ..To evaluate the efficacy and tolerability of indinavir/ritonavir (IDV/RTV) 400/100 mg twice daily in combination with two nucleoside reverse transcriptase inhibitors in antiretroviral-naive patients...
  31. ncbi Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level
    Marc Wirden
    J Acquir Immune Defic Syndr 36:876-8. 2004
  32. ncbi Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA
    Marc-Antoine Valantin
    Departement des Maladies Infectieuses et Tropicales, , , Paris, France
    AIDS 17:2471-7. 2003
    ..The efficacy, safety profile, and the simplicity of the injection schedule of PLA make this filling material a potentially attractive treatment...
  33. ncbi Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men
    Jade Ghosn
    Laboratoire de Virologie, , France
    AIDS 18:1958-61. 2004
    ..These are worrying findings, because suboptimal semen drug concentrations may enhance the risk of sexually transmitted drug-resistant HIV variants...
  34. ncbi MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study
    Christine Katlama
    Département des Maladies Infectieuses et Tropicales INSERM E0214, Hopital Pitie Salpetriere, Paris, France
    AIDS 18:1299-304. 2004
    ..MIV-310 (alovudine), a nucleoside reverse transcriptase inhibitor, potently inhibits the replication of highly mutated strains of HIV in vitro. We examined the efficacy of MIV-310 in highly pretreated patients...
  35. ncbi No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients
    Jade Ghosn
    Department of Infectious and Tropical Diseases, , Paris, France
    AIDS 19:1643-7. 2005
    ....
  36. ncbi Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir
    Jade Ghosn
    Clin Infect Dis 41:1360-1. 2005
  37. ncbi Liver fibrosis and antiretroviral therapy
    Jade Ghosn
    Clin Infect Dis 42:271-2. 2006
  38. ncbi Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients
    Stephanie Dominguez
    Department of Infectious and Tropical Diseases INSERM U 720, CHU Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    AIDS 20:1157-61. 2006
    ..Treatment of acute hepatitis C (HCV) in HIV-infected patients has been poorly addressed...
  39. ncbi Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, 75013 Paris, France
    Antimicrob Agents Chemother 50:2553-6. 2006
    ..L74I was strongly associated with T215F, K70R, and V75M/S/T/A mutations and increased with the number of thymidine analog mutations. It seemed to be linked to the use of abacavir or efavirenz...
  40. ncbi Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance
    Ana Canestri
    Department des Maladies Infectieuses, , Paris, France
    Antivir Ther 11:561-6. 2006
    ..CONCLUSION: In patients with HIV mutations conferring resistance to all antiretroviral drug classes, foscarnet markedly reduced plasma HIV load and improved immunological status...
  41. ncbi Warning: antiretroviral treatment interruption could lead to an increased risk of HIV transmission
    Roland Tubiana
    AIDS 16:1083-4. 2002
  42. ncbi HIV-2 infection and HIV-associated nephropathy
    Hassane Izzedine
    AIDS 20:949-50. 2006